RU2053767C1 - Complex therapeutic preparation for veterinary - Google Patents

Abstract

FIELD: veterinary. SUBSTANCE: preparation has components of nitrofuran order, immunostimulating agent and milk protein fraction base. Furacrilin is used from preparations of nitrofuran order and methyluracil is used as immunostimulating agent. Except for, complex has additionally novocain and ethacridine lactate at the following ratio of components, wt.-%: furacrilin 1.6-2; ethacridine lactate 1-1.5; methyluracil 1-2; novocain 0.5-1.0, and milk protein fraction - the rest. Preparation is used for treatment of young animals with gynecological disease in cows, gastro-intestinal diseases. EFFECT: enhanced quality of preparation, stability at storage (for 2 years), absence of by-side effects. 5 tbl

Description

 The invention relates to drugs, in particular to drugs used in veterinary medicine for the treatment of animals with gastrointestinal diseases, such as salmonellosis, colinfection, dysentery; respiratory organs of young animals, including rickettsial etiology; obstetric and gynecological diseases, including mastitis, endometritis, as well as rickettsial etiology.

 It is known to use antibacterial drugs to treat these diseases. Nitrofuran preparations were widely used.

 The disadvantage of using these drugs is that during treatment it is necessary to carry out, for the indicated infections, not only etiotropic treatment, but also rational conduct of vicarial therapy, stimulating therapy, pathogenetic therapy, and the use of only nitrofuran series drugs does not allow this. Or you have to use a number of other drugs at the same time. In turn, this leads to additional manipulations with animals, with their separate introduction. In addition, a thorough study of the compatibility of the administered drugs and their actions in the animal's body with simultaneous administration is required.

 In this case, in practice, it is most optimal to use complex preparations that simultaneously perform all of these functions.

Closest to the invention is the bactericidal preparation "lactobril". This preparation contains furazolidone, brilliant green, potassium iodide, chloroform and a food structuring concentrate in the following ratio of components: wt. Furazolidone 1.0-1.5
Diamond green 0.3-0.5 Potassium iodide 2.5-3.0 Chloroform 1.5-2.0
Concentrate
Structuring Food Else
The drug has an antimicrobial effect on gram-positive bacteria, bactericidal for Staphylococcus aureus. Activates tissue regeneration. It has a fairly high degree of efficiency and stability during storage.

 However, like any antimicrobial drug, in the process of getting used to it, when it is used, it may not be the death of the pathogen, but its increased resistance, when it even reproduces better in the presence of the drug. Therefore, one of the ways to increase the therapeutic efficacy of antimicrobials is to expand their range, which can prevent the formation of resistant strains and reduce adverse reactions.

 The disadvantage of the drug, with all its positive qualities, is that it is not effective against rickettsia and associations of pyogenic microflora. In addition, the main antibacterial component of the nitrafuran series furazolidone affects the immunological status of the body and despite the introduction of potassium iodide as a stimulant, it is not possible to get rid of this negative characteristic.

 The use of brilliant green in the Lactobril complex preparation on the one hand provided it with the opportunity to use it as a contracted drug, but on the other hand, it is not recommended to use it as an internal medicine in pharmacological practice.

 The aim of the invention is to provide the possibility of expanding the range of complex therapeutic drugs with a wide spectrum of action.

The essence of the alleged invention lies in the fact that the preparation contains components of the nitrofuran series, an immunostimulant and a base from the protein fraction of milk. Furacrilin is used as a component of the nitrofuran series. As an immunostimulant, methyluracil. In addition, novocaine and ethacridine lactate were additionally introduced. All of these components are taken in the ratio, wt. Furacrilin 1.5-2.0
Ethacridine Lactate 1.0-1.5 Methyluracil 1.0-2.0 Novocain 0.5-1.0
Components
milk protein fraction
After analyzing the literature and patent documentation known to us, we came to the conclusion that the complex preparation we are offering is not known. All components included in it are approved for use in pharmacological practice. However, the use of each of them individually, or in other known combinations, does not give the effect inherent in the Biofenom drug.

 The characteristic of each of the introduced components is as follows.

 Ethacridine lactate is included in the complex preparation as a strong antimicrobial agent. It belongs to the group of paints, has a quick bacteriostatic effect on a number of microorganisms, (including pyogenic) officially approved for use inside.

 In addition, it is firmly adsorbed on the mucous membranes and wounds, staying on them for up to a day, during all this time it is active.

 All these properties distinguish it from other drugs of this group, including brilliant green. Against the background of the pronounced bacteriostatic effect of ethacridine lactate, the antibacterial (including bactericidal) function of the complex drug comes into play, due to the presence of furacrilin in it. Its effect is due to the presence of furan and triazole rings. It surpasses furazolidone and furazonal close to it by 5-25 times in chemical and antimicrobial activity. It has an antimicrobial effect on grams (+) and grams (-) bacteria, especially pyogenic bacteria.

 It is highly active against pathogens of dysentery, colienteritis, listeriosis and antibiotic-resistant microbes. Furacryline is low toxic. It does not have a cumulative effect. When administered orally in therapeutic doses, it is well absorbed and stored in the blood for 6 hours in effective doses. Increases the phagocytic activity of leukocytes. It does not violate the activity of the cardiovascular system, does not change respiration, does not affect the composition of the blood.

 Simultaneously with the selected successful combination of bacteriostatic action and bactericidal action, a pathogenetic agent is acting in parallel, which affects the mechanism of development of the pathological process of novocaine. It normalizes the excitability and permeability of nerve fibers, restores vascular tone and permeability, improves trophic tissue, stimulates phagocytosis. At the same time, the mechanisms of immunogenesis and regeneration are activated due to the presence of components such as methyluracil and the protein fraction of milk, for example, whole milk substitutes (milk replacer) or food structuring concentrate (PCP).

 The experimental data presented indicate the presence of a synergistic effect of all the components included in the complex preparation, which is confirmed by the experimental data included in Table 1.

 Conclusion: the presence of a synergistic effect is confirmed by the results of an experiment conducted on groups of sick animals. The effectiveness of Biofenom treatment is 12-17% higher than with other drugs.

 Empirical observations have also pointed to the positive effect of Biofenoma in diseases of rickettsial and polymicrobial etiology. In addition to the well-known characteristics of each component when using them separately, it was possible to establish that their inclusion in the composition of "Biophenome" expanded and changed their therapeutic effect. So the effect of ethacridine lactate intensified in the presence of organic substances (milk replacer, KSP).

 The spectrum of action of methyluracil expanded in the preparation. He contributed to the implementation of anti-necrotic action. As for novocaine, it not only carries out the well-known functions of pathogenetic therapy, but also enhances the absorption of all components of the drug, thereby increasing its effectiveness. In general, the antibacterial components taken as part of the drug arose in doses of smaller generally accepted therapeutic ones when used separately, which can also be considered one of the successful aspects of the drug.

 Single dose calculations are given on calves with an average weight of 50 kg. For 1 dose, 5 ml of the packaged native preparation is taken. All calculations are given in terms of pure substances.

 Conclusion: single doses of the use of components in the "Biophenoma" are reduced compared with doses with the independent use of each of them.

 Conclusions: in therapeutic treatment, the selected dose is most effective.

 The use of the drug in doses below the minimum applied by 0.3% significantly reduces the therapeutic effect. In this case, only 53% of the animals recover. The use of a variant of the drug with doses of components higher by 0.3% of the proposed maximum did not increase the effectiveness of the drug. Moreover, the number of calves recovered and the appearance of the first signs of recovery corresponded to the use of maximum dosage values.

 Thus, the results of the analysis allowed us to conclude that the proposed drug meets the criteria of novelty and inventive step.

The drug is made as follows:
all components are individually ground in a porcelain mortar and alternately introduced into the container in an amount of g per 1000 ml: furacryline 15-20 (1.5-2.0%); ethacridine lactate 10-15 (1.0-1.5%); methyluracil 10-20 (1-2%); novocaine 5-10 (0.5-1.0%).

Then mixed with any protein fraction of milk, bringing the mixture to 1000 ml. That is, with so many components of the protein fraction of milk introduced into the preparation, up to 1000 ml is added (the rest). It can be milk replacer or PCB, or any other filler from the protein fraction of milk. The mixture is thoroughly mixed using equipment, depending on which protein fraction of milk was taken. If you took a milk replacer (dry), then mix it with a mixer or ball mill, if the liquid fraction, for example, PCB, then mix it on a shooter machine. Mixing is carried out to a uniform homogeneous mass. Then carry out the packing of 5.0 (+0.2 ml) in vials for medical preparations with a volume of 20.0 ml. Next, the vials with the contents are frozen and lyophilized by a known method, if the liquid protein fraction of milk (KSP) is taken as a filler. If WMS is taken as a filler, then the drug is immediately packaged. The net weight of the drug in one bottle after drying is 0.5 g (± 10 mg) and is taken conditionally for one therapeutic dose. In the case of packaging the drug in a dry form, the amount of the drug weighing 5 g is taken per dose. The shelf life of the drug is 2 years from the date of manufacture, provided that it is stored in a dry, closed from sunlight at 8-10 ^o C.

 Examples of execution.

 “Biofenom” is technologically reproducible in the boundary and average values of the ingredients, which is confirmed by the experimental production of three series, wt.

1. A series of the drug N 1 Furacrilin 1.5 Ethacridine lactate 1.0 Methyluracil 1.0 Novocain 0.5
Protein fraction of milk (KSP) Else
2. A series of the drug N 2 Furakrilin 1.75
Ethacridine Lactate 1.25 Methyluracil 1.5 Novocaine 0.75
Protein
milk fraction (PCB)
3. A series of the drug N 3 Furacrilin 2.0 Ethacridine lactate 1.5 Methyluracil 2.0 Novocain 1.0
Protein
milk fraction (PCB)
Technologically, each series was reproduced as follows:
all components were individually ground in a porcelain mortar and alternately introduced into the container in an amount according to a series of 1,2,3. Then mixed with any protein fraction of milk. In this case, a food structuring concentrate was taken. The mixture was thoroughly mixed on a shuttle apparatus until a homogeneous mass was formed.

The resulting mass was Packed in vials for medical purposes with a volume of 20.0 ml Next, the contents of the vials were frozen at - (- 40 ^C) and lyophilized. The net weight of the drug in one bottle after drying was 0.5 g (± 10 mg). It is taken conditionally for one therapeutic dose (or 5 g of dry packaging). The shelf life of the drug was 2 years from the date of manufacture.

 The preparation of each series obtained: the minimum number of ingredients (series 2) and the maximum number of ingredients (series 3) were experimentally tested in animals. The verification results are shown in table 4.

 Conclusions: testing using each series of the drug confirmed the uniform therapeutic efficacy of each series in the selected range of ingredients.

 Production tests of "Biofenoma" were carried out in three farms of the Stavropol Territory: to them Lenin; c-s of Stravropol-Kavkazsky (Petrovsky district); to "Way of Lenin" (Turkmen region). According to the data of each farm, average indicators (prefabricated groups) are derived.

 The test results are shown in table 5.

 The drug was used as follows.

 1. Postpartum endometritis of polymicrobial etiology (including rickettsial).

After 2-3 hours after surgical department-delayed placenta (placenta), and after its separation incomplete, in cases of abortion and pathological genera 2 vials drug contents were dissolved in 150 ml cooled to 37-40 ^{° C} boiling water and administered 1 time per day intrauterine device.

 1.1. In order to prevent post-transplant endometritis in donor cows, the latter, after nonsurgical or surgical extraction of embryos, injected into the uterine horn cavity 2 vials of the drug dissolved in 20 ml of boiled water or saline.

 2. Mastitis subclinical, acute, serous and catarrhal.

 In order to treat cows with mastitis, the contents of 1 vial or 5 g of dry packaged preparation was dissolved in 20 l of boiled water, instilled intracisternally with a milk catheter through the nipple canal, after the breast contents were crushed, 2 times a day in the morning and in the evening in a sick quarter udder.

 3. Gastroenterocolitis of salmonella, colibacteriosis, desinteria and associated etiology.

 The contents of 1 bottle or 5 g of dry packaged preparation was dissolved in 100-150 ml of boiled water and the calf was given inside 15-20 minutes before feeding with colostrum 2 times a day in the morning and in the evening.

 4. For the treatment of infected wounds, abscesses and burns, the contents of 1 bottle or 5 g of the drug was dissolved in 20 ml of boiled water and applied to the surface of the wound or irrigated the cavity of the opened abscess after preliminary sanitization. The use of the drug in the form of 2-3% ointments on a fat basis is allowed.

 5. In the treatment of bronchopneumonia of young polymicrobial (including rickettsial) etiology, 2 vials of the preparation or 10 g of dry preparation were taken, dissolved in 100-150 ml of boiled water and evaporated to the animal 2 times a day. The average course of treatment is 6-7 days.

 Production tests showed that the therapeutic effect of Biofenoma was higher than with other drugs. So the course of treatment "Biophenoma" for endometritis and mastitis was 4-5 days, for gastroenteritis 5-6 days, and for bronchopneumonia 6-7 days, while the course of treatment "Lactobril" of endometritis and mastitis on average for 2-3 days longer. In diseases of rickettsial etiology and bronchopneumonia of any etiology, Lactobril is generally not effective. Furacryline is close to Biofenom in its spectrum of action, but the healing process is lower (Table 1), and the course of treatment for all diseases is longer by an average of 1-2 days.

 Thus, preliminary tests of the drug testify to its objective advantages compared to well-known therapeutic agents: a wide range of therapeutic effects that provide efficacy in the treatment of gynecological diseases of cows, gastrointestinal diseases of young animals, etc. does not have a side effect on the animal organism; it is soluble in water, compact, light and convenient for transportation and practical use, stable during storage for 2 years.

Claims (1)

A complex therapeutic drug for veterinary medicine containing components of the nitrofuran series and the basis of the protein fraction of milk, characterized in that it contains furacryline as the drug of the nitrofuran series and methinuracil and additionally procaine and ethacridine lactate as the immunostimulant in the following ratio, wt.%:
Furacryline - 1.5 - 2.0
Methyluracil - 1.0 - 2.0
Novocain - 0.5 - 1.0
Ethacridine Lactate - 1.0 - 1.5
Milk Protein - Other

Images